as of 04-14-2026 3:39pm EST
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
Frequently Asked Questions
Learn more about our ERNA ML prediction model
What parameters are used to train the ERNA ML model?
Our stocks ERNA ML model is trained using historical data with over 25 parameters, including volume indicators, volatility indicators, momentum indicators, trend indicators, and other technical metrics.
How often is the ERNA ML model updated?
We update our ML model weekly or biweekly (depending on market capitalization) using TensorFlow, typically over the weekend to ensure the most current predictions.
Why might the model accuracy vary?
Our current data provider offers limited historical data, which can impact accuracy. As we continue to gather more data and add additional indicators, we expect the model's accuracy to improve over time.
How can I contribute data to improve accuracy?
We greatly appreciate contributions! Please contact us at info@finquota.com to discuss how you can help improve our models.
Are shorter timeframe predictions available?
Yes, we offer predictions for strategy purposes with shorter intervals including 1 minute, 2 minutes, 5 minutes, 15 minutes, and 30 minutes timeframes.
Should I use this for financial decisions?
Our ML model is designed for educational purposes only and should not be used as the sole basis for financial decisions. Always consult with a qualified financial advisor before making any investment decisions.
Share on Social Networks:
Disclaimer
Our ERNA ML model is developed exclusively for educational purposes. Any information presented on this page regarding the '"ERNA Forecast & Prediction for April 15, 2026 Eterna Therapeutics Inc." should not be considered as financial advice or as a recommendation to buy or sell stocks. It is provided strictly for educational purposes. Investing in stocks involves significant risks, and decisions should be made only after careful consideration and consultation with a qualified financial advisor.